Advertisement

Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors

  • T. Jiang
  • B. J. WeiEmail author
  • D. X. ZhangEmail author
  • L. LiEmail author
  • G. L. Qiao
  • X. A. Yao
  • Z. W. Chen
  • X. Liu
  • X. Y. Du
Original Article
  • 48 Downloads

Abstract

Summary

Diagnosis of parathyroid carcinoma on histological examination is challenging. Thousands of differentially expressed lncRNAs were identified on the microarray data between parathyroid cancer and adenoma samples. Four lncRNAs were significantly dysregulated in further validation. The “lncRNA score” calculated from these lncRNAs differentiated parathyroid carcinomas from adenomas. LncRNAs serve as biomarkers for parathyroid cancer diagnosis.

Introduction

Diagnosis of parathyroid carcinoma (PC) on histological examination is challenging. LncRNA profile study was conducted to find diagnostic biomarkers for PC.

Methods

LncRNA arrays containing 91,007 lncRNAs as well as 29,857 mRNAs were used to assess parathyroid specimen (5 carcinomas and 6 adenomas). Bioinformatics analyses were also conducted to compare the microarray results between parathyroid carcinomas and adenomas (PAs). Differentially expressed lncRNAs of 11 PCs and 31 PAs were validated by real-time quantitative PCR.

Results

On the microarray data between PC and PA samples (fold change ≥ 2, P < 0.05), 1809 differentially expressed lncRNAs and 1349 mRNAs also were identified. All carcinomas were clustered in the same group by clustering analysis using dysregulated lncRNAs or mRNAs. Four lncRNAs (LINC00959, lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2:1) identified were significantly dysregulated in further RT-PCR validation. The global “lncRNA score” calculated from the lncRNAs above also differentiated parathyroid carcinomas from adenomas.

Conclusions

LncRNA profiling shows distinct differentially expressed lncRNAs in parathyroid neoplasm. They may play a key role in parathyroid cancer and serve as potential biomarkers to distinguish parathyroid cancers from parathyroid adenomas.

Keywords

diagnosis hyperparathyroidism lncRNAs parathyroid tumors 

Abbreviations

PC

parathyroid carcinoma

PA

parathyroid adenoma

lncRNA

long non-coding RNA

mRNA

messenger RNA

GO

gene ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

RT-qPCR

reverse-transcription quantitative polymerase chain reaction

Notes

Author contributions

TJ, BJW, DXZ, and LL designed research; ZWC, GLQ, and XAY conducted acquisition of data; technical/material supports were provided by ZWC, XL, and XXD; technical/material support TJ, BJW, DXZ, and LL performed research and statistical analysis; TJ, BJW, DXZ, and LL wrote the paper; and BJW, DXZ, and LL conducted a critical revision of the manuscript.

Funding information

This research was funded by Project of Science and Technology Research and Development of China Railway Corporation (No. J2017Z603), Special Project of Profession (No.201402007), and Foundation for young of Beijing Shijitan Hospital (2018-q13).

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Supplementary material

198_2019_4959_MOESM1_ESM.docx (573 kb)
ESM 1 (DOCX 572 kb)

References

  1. 1.
    DeLellis RA, Mazzaglia P, Mangray S (2008) Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 132(8):1251–1262PubMedGoogle Scholar
  2. 2.
    Schulte KM, Talat N (2012) Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 8(10):612–622CrossRefPubMedGoogle Scholar
  3. 3.
    Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40(9):657–663CrossRefPubMedGoogle Scholar
  4. 4.
    Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349(18):1722–1729CrossRefPubMedGoogle Scholar
  5. 5.
    Haven CJ, van Puijenbroek M, Tan MH, Teh BT, Fleuren GJ, van Wezel T, Morreau H (2007) Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol 67(3):370–376CrossRefGoogle Scholar
  6. 6.
    Yu W, McPherson JR, Stevenson M et al (2015) Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. J Clin Endocrinol Metab 100(2):E360–E364CrossRefPubMedGoogle Scholar
  7. 7.
    Schmitt AM, Chang HY (2013) Gene regulation: long RNAs wire up cancer growth. Nature. 500(7464):536–537CrossRefPubMedGoogle Scholar
  8. 8.
    Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 458(7235):223–227CrossRefPubMedGoogle Scholar
  9. 9.
    Silva A, Bullock M, Calin G (2015) The clinical relevance of long non-coding RNAs in Cancer. Cancers (Basel) 7(4):2169–2182CrossRefGoogle Scholar
  10. 10.
    Knoll M, Lodish HF, Sun L (2015) Long non-coding RNAs as regulators of the endocrine system. Nat Rev Endocrinol 11(3):151–160CrossRefPubMedGoogle Scholar
  11. 11.
    Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25(1):25–29CrossRefPubMedGoogle Scholar
  12. 12.
    Corbetta S, Vaira V, Guarnieri V, Scillitani A, Eller-Vainicher C, Ferrero S, Vicentini L, Chiodini I, Bisceglia M, Beck-Peccoz P, Bosari S, Spada A (2010) Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer 17(1):135–146CrossRefPubMedGoogle Scholar
  13. 13.
    Al-Kurd A, Mekel M, Mazeh H (2014) Parathyroid carcinoma. Surg Oncol 23(2):107–114CrossRefPubMedGoogle Scholar
  14. 14.
    Kebebew E, Arici C, Duh QY, Clark OH (2001) Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136(8):878–885CrossRefPubMedGoogle Scholar
  15. 15.
    Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma. Eur J Endocrinol 156(5):547–554CrossRefPubMedGoogle Scholar
  16. 16.
    Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH (2009) Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 115(2):334–344CrossRefPubMedGoogle Scholar
  17. 17.
    Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, Robinson BG, Teh BT, Gimm O, Marsh DJ (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94(2):434–441CrossRefPubMedGoogle Scholar
  18. 18.
    Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR (2014) Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg 38(11):2845–2854CrossRefPubMedGoogle Scholar
  19. 19.
    Hu Y, Liao Q, Cao S, Gao X, Zhao Y (2016) Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. Endocrine. 54(3):612–619CrossRefPubMedGoogle Scholar
  20. 20.
    Wei CH, Harari A (2012) Parathyroid carcinoma: update and guidelines for management. Curr Treat Options in Oncol 13(1):11–23CrossRefGoogle Scholar
  21. 21.
    Murugan AK, Munirajan AK, Alzahrani AS (2018) Long noncoding RNAs: emerging players in thyroid cancer pathogenesis. Endocr Relat Cancer 25(2):R59–R82Google Scholar
  22. 22.
    Perlis N, Al-Kasab T, Ahmad A, Goldberg E, Fadak K, Sayid R, Finelli A, Kulkarni G, Hamilton R, Zlotta A, Ghai S, Fleshner N (2018) Defining a cohort that may not require repeat prostate biopsy based on PCA3 score and magnetic resonance imaging: the dual negative effect. J Urol 199(5):1182–1187Google Scholar
  23. 23.
    Dijkstra S, Mulders PF, Schalken JA (2014) Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem 47(10–11):889–896CrossRefPubMedGoogle Scholar
  24. 24.
    Zhang D, Liu X, Wei B, Qiao G, Jiang T, Chen Z (2017) Plasma lncRNA GAS8-AS1 as a potential biomarker of papillary thyroid carcinoma in Chinese patients. Int J Endocrinol 2017:2645904PubMedGoogle Scholar
  25. 25.
    Leelahavanichkul K, Amornphimoltham P, Molinolo AA, Basile JR, Koontongkaew S, Gutkind JS (2014) A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. Mol Oncol 8(1):105–118CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang HJ, Tao J, Sheng L, Hu X, Rong RM, Xu M, Zhu TY (2016) Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. Onco Targets Ther 9:1801–1812PubMedGoogle Scholar
  27. 27.
    Hoskin V, Szeto A, Ghaffari A, Greer PA, Côté GP, Elliott BE (2015) Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer cell invasion. Mol Biol Cell 26(19):3464–3479CrossRefPubMedGoogle Scholar
  28. 28.
    Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9(2):95–107CrossRefPubMedGoogle Scholar
  29. 29.
    Muller PA, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15(1):2–8CrossRefPubMedGoogle Scholar
  30. 30.
    Jo JH, Chung TM, Youn H, Yoo JY (2014) Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis. Nat Commun 5:5433CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang A, Xu M, Mo YY (2014) Role of the lncRNA-p53 regulatory network in cancer. J Mol Cell Biol 6(3):181–191CrossRefPubMedGoogle Scholar
  32. 32.
    Rather MI, Nagashri MN, Swamy SS, Gopinath KS, Kumar A (2013) Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. J Biol Chem 288:608–618CrossRefPubMedGoogle Scholar
  33. 33.
    Hahn MA, Howell VM, Gill AJ, Clarkson A, Weaire-Buchanan G, Robinson BG, Delbridge L, Gimm O, Schmitt WD, Teh BT, Marsh DJ (2010) CDC73/HRPT2 CpG island hypermethylation and mutation of 5′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr Relat Cancer 17:273–282CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  1. 1.Department of Endocrinology, Beijing Shijitan HospitalCapital Medical UniversityBeijingChina
  2. 2.Department of Otorhinolaryngology, Beijing Shijitan HospitalCapital Medical UniversityBeijingChina
  3. 3.Department of Thyroid and Neck Surgery, Beijing Chaoyang HospitalCapital Medical UniversityBeijingChina
  4. 4.Department of Pediatric SurgeryCapital Institute of PediatricsBeijingChina
  5. 5.Department of Medical Oncology, Beijing Shijitan HospitalCapital Medical UniversityBeijingChina
  6. 6.Department of Medical Genetics and Developmental BiologyCapital Medical UniversityBeijingChina

Personalised recommendations